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Over the past decade, basic research has established alo-
pecia areata as a T cell^mediated autoimmune disease
and has clari¢ed many of its genetic, cellular, and mo-
lecular aspects. Perifollicular and intrafollicular mono-
nuclear cell in¢ltrates directed at anagen hair bulbs are
characteristic and striking histologic features in early
alopecia areata. The in£ammatory in¢ltrate is com-
posed predominantly of activated CD4þ and CD8þT
cells, together with macrophages and Langerhans cells.
The initiation phase of alopecia areata is mediated by
type 1 cytokines, including interleukin-2, interferon-c,
and tumor necrosis factor-a. Like other diseases with a
strong autoimmune component, alopecia areata has as-
sociated with it speci¢c human leukocyte antigens,
which determine susceptibility, severity, chronicity, and
resistance. New topical immunomodulating drugs and
biologic therapies that have been developed, or that are
in development, for the treatment of other immune-
mediated in£ammatory skin diseases will likely be ef-
fective in alopecia areata as well. The present discussion
addresses the treatment of alopecia areata within the
framework of these new modalities. Keywords: lympho-
cytes/macrophages/Langerhans cells/immunomodulating drugs/
biologic therapies. JID symposium Proceedings 8:207 ^211,
2003
A
lopecia areata (AA) disrupts many lives, young and
old, because of its recurrent episodes of erratic, un-
predictable, patchy hair loss and sometimes long-
standing loss of all scalp hair (alopecia totalis, AT)
or loss of all scalp and body hair (alopecia universa-
lis, AU). Over the past decade, the International ResearchWork-
shops on Alopecia Areata have stimulated essential basic research
in this disease. These e¡orts, supported in large part by the Na-
tional Alopecia Areata Foundation (NAAF), have established AA
as a T cell^mediated autoimmune disease (Gilhar et al, 1998; Gil-
har et al, 2001) and have clari¢ed many of its genetic, cellular, and
molecular aspects. As a result, new therapies will likely become
available to those who su¡er from AA.
Approximately 2% of the population are at a lifetime risk of
su¡ering from AA, which occurs worldwide (Safavi et al, 1995).
Hair loss usually occurs in distinct bare patches on the scalp. In
approximately 5% of cases, the disease progresses to AT/AU (Sa-
favi et al, 1995). Persons with AA are usually otherwise healthy,
and the disease occurs in all age groups, although children and
young persons are a¡ected most commonly.
Perifollicular and intrafollicular mononuclear cell in¢ltrates are
characteristic and striking histologic features in earlyAA. The in-
£ammatory in¢ltrate is directed at anagen hair bulbs and is com-
posed predominantly of activated CD4þ and CD8þT cells,
together with macrophages and Langerhans cells (Bodemer et al,
2000; Gilhar et al, 2002). The intrafollicular in¢ltrate is composed
predominantly of CD8þT cells, in contrast to the perifollicular
in¢ltrate, which is composed primarily of CD4þT cells (Todes-
Taylor et al, 1984; Khoury et al, 1992; Gilhar et al, 2002). Depletion
of either activated CD8þ or CD4þT cells restores hair growth
in the Dundee experimental bald rat (DEBR) model (McElwee
et al, 1996; McElwee et al, 1999). A T cell^directed therapeutic ap-
proach may also be relevant for hair regrowth in humans. The
fact that there is no obvious cellular destruction or any progres-
sive cumulative damage in AA suggests that the presence of
CD8þT cells may signal not a cytotoxic role in AA but rather
a regulatory or suppressor cell function. Scalp biopsies from pa-
tients and from the AA mouse model show a heavy presence of
type 1 cytokines, including interleukin-2 (IL-2), interferon-g
(IFN-g), and tumor necrosis factor-a (TNF-a) (Ho¡mann et al,
1994; Ho¡man, 1999; Carroll et al, 2002). Possible therapies may
include agents directed against these cytokines.
As with other diseases with a strong autoimmune component,
speci¢c human leukocyte antigens (HLA) are associated with AA
and determine susceptibility, severity, chronicity, and resistance
(Welsh et al, 1994; Price and Colombe, 1996; Colombe et al, 1999).
The HLA class II allele, DQB103, is a general marker for AA
susceptibility and is present in over 80% of all AA patients.
Moreover, the allele DRB11104 is over 10 times more frequent
in all types of AA than in a control population. Markers for se-
verity and chronicity appear to be HLA-DQB10301 and
DRB10401, which are both signi¢cantly increased in long-
standing AT and AU. Two clinical types of AA, patchy AA and
AT/AU, are thus distinguishable at the molecular level by a ge-
netically based predisposition to the extent of disease.
Current traditional therapies are predominantly immuno-
modulating modalities, including corticosteroids, topical im-
munotherapy, anthralin, and photochemotherapy (PUVA). A
nonspeci¢c modality is topical minoxidil, which prolongs ana-
gen and promotes growth of longer and wider hair (Price, 1999;
Wiseman et al, 2001). These treatments have been used for
many years, and new targeted therapies are particularly needed
for children, for those with chronic, persistent patchy disease,
and for those with AT and AU (the most extensive forms of the
disease).
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THERAPIES FOR ALOPECIA AREATA: ‘‘ON THE CUSP’’
New topical immunomodulating drugs and biologic therapies
have been developed, or are in development, for the treatment
of immune-mediated in£ammatory skin diseases such as atopic
dermatitis and psoriasis (Krueger, 2002; Singri et al, 2002). This
has followed years of basic research, which has helped to clarify
the complex immunopathogenesis for both of these diseases.
Over the past decade, extensive basic research has shown that
AA is also a T cell^mediated autoimmune skin disease, with
many features similar to psoriasis, and that it is an excellent can-
didate for these same therapies.
The immunopathologic features of psoriasis have provided the
basis of a conceptual model for rationally designed biologic thera-
pies. Gordon and colleagues have suggested four strategies within
this model: (i) reduction of pathogenicTcells, (ii) inhibition of T
cell activation, (iii) shifting a type 1 cytokine response to a type 2
response, and (iv) blocking activity of in£ammatory cytokines
(Singri et al, 2002). This therapeutic model is also applicable to
the new immunomodulating drugs used in atopic dermatitis.
The present discussion addresses the treatment of alopecia areata
in the framework of this conceptual model.
New ImmunomodulatoryTherapies Topical immunomodu-
lators are a new class of agent that acts locally on T cells by
suppressing cytokine transcription (Schneider, 2002). The two
most studied topical immunomodulators are tacrolimus and
pimecrolimus. A third new member of this group is topical
cyclosporine (CsA). All three drugs inhibit calcineurin, thereby
inhibiting IL-2 production.
Topical tacrolimus (Protopic) Tacrolimus has been used for
many years to prevent organ rejection after liver or kidney
transplantation. It acts directly on T cells to inhibit IL-2
transcription, which results in decreased growth and pro-
liferation of T lymphocytes in response to foreign antigens
(Lawrence, 1998). It also inhibits other cytokines, including
TNF-a and IFN-g, both important in T cell activation. Like
other systemic immunosuppressants, oral tacrolimus is associated
with signi¢cant side e¡ects, such as kidney and liver impairment
and hypertension. Several studies have demonstrated the safety
and e⁄cacy of topical tacrolimus ointment in patients with atopic
dermatitis.The topical formulation has been studied in more than
10,000 patients worldwide and appears to have no signi¢cant
systemic side e¡ects (Schneider, 2002). It is FDA-approved for
treatment of atopic dermatitis in children two years of age or
older and on all parts of the body, including the face. Tacrolimus
ointment does not cause skin atrophy, pigment changes, or
telangiectasia.
The ointment formulation, however, may not be optimal
for AA (Thiers, 2000). A clinical trial in patients with AA
was recently completed in the Department of Dermatology,
University of California, San Francisco. Seventeen patients, with
AA, a¡ecting 25% to 75% of the scalp for more than 12 months,
were enrolled in a single-center, open-label study. Tacrolimus
ointment 0.1% was applied twice daily for 24 weeks, and
patients were observed for six additional weeks after stopping
treatment. Six patients dropped out of the study because the
ointment formulation was too greasy for the scalp or because of
scheduling problems. Eleven patients completed the study, and all
showed either no change in their hair growth or further hair loss
(Submitted for publication). Another study reported ¢ve patients
with long-standing, treatment-resistant alopecia universalis who
applied 0.1% tacrolimus ointment once daily for six months;
none had hair regrowth (Feldmann et al, 2002). Treatment failure
in patients with long-standing alopecia universalis is not
surprising, as their response to existing treatments is generally
poor and they may not be appropriate for evaluating the e⁄cacy
of new modalities.
Perhaps hair growth promotion with immunomodulatory
agents such as tacrolimus will be more successful in patients who
still have a dense dermal T cell in¢ltrate, as in patients whose AA
is of short duration (i.e., 3^12 months) or who have chronic,
active patchy disease. In such patients, larger, placebo-controlled
trials are necessary for assessing results. A less greasy formula-
tion of tacrolimus may improve drug delivery, e⁄cacy, and
compliance with scalp application.
Topical pimecrolimus (Elidel) Pimecrolimus, an ascomycin
derivative, is a cell-selective cytokine inhibitor developed for the
treatment of in£ammatory skin diseases (Meingassner et al, 1997).
It binds to macrophilin-12; inhibits calcineurin; inhibits synthesis
of in£ammatory cytokines, such as IL-2 and INF-g; and inhibits
T cell and mast cell activation. Pimecrolimus has high skin-
speci¢c anti-in£ammatory activity with low potential for
a¡ecting the systemic immune response. The cream 1%
formulation is safe and e¡ective for atopic dermatitis and does
not cause skin atrophy or telangiectasia (Eichen¢eld et al, 2002).
Unfortunately, the cream is not expected to be e¡ective for hair
regrowth because it permeates no lower than the super¢cial
dermis, which is an insu⁄cient depth for targeting T cells
involved in AA. Oral pimecrolimus is in clinical trials in
psoriasis and, like the cream formulation, does not cause
systemic immunosuppression and is inactive in transplant
models. Clinical trials with the oral drug are eagerly awaited
in AA.
Topical cyclosporine A (PsorBan) The use of oral CsA to
treat severe in£ammatory skin diseases is well established. Oral
CsA is also e¡ective in the short-term treatment of alopecia
areata (Gupta et al, 1990); however, the inherent toxicity
associated with systemic administration precludes its value in
treating chronic skin diseases that, while serious, are not life
threatening. In the past, topical formulations of CsA were
ine¡ective because of poor skin penetration. To surmount this
problem, a heptamer of arginine was conjugated to CsA through
a pH-sensitive linker designed to release CsA at physiologic
pH within the skin (Rothbard et al, 2000). The oligoarginine
transporters enable full-skin-thickness penetration of CsA
into cells throughout the epidermis and dermis of murine
and human skin, with functional inhibition of cutaneous
in£ammation.1
Preclinical safety testing with topical CsA has been completed,
and the formulation has a clean toxicity pro¢le. A phase II
multicenter psoriasis study is in progress. Clinical trials in AA
with topical CsA are pending and will be of great interest,
although the current formulation is greasy and designed for
glabrous skin and so reformulation for the scalp will be needed.
New Biologic Therapies Biologic agents are proteins that
possess pharmacologic activity and can be extracted from tissue.
With the development of recombinant DNA technology,
biologic agents can be synthesized in large quantities and
designed to alter speci¢c physiologic responses (Singri et al,
2002). Biologic therapies target cell surface receptors, and their
theoretical advantage is that their greater speci¢city will provide
better safety pro¢les. Biologics are larger than ‘‘small-molecule’’
drugs and are most often administered by injection (sub-
cutaneous, intramuscular, or intravenous).
AA is mediated by activated T cells. The process of activation
requires two signals between T cells and antigen- presenting cells
(APCs). Signal 1 involves the presentation of a speci¢c antigen by
the MHC (HLA) molecule on the surface of the APC and its
recognition by its speci¢c T cell receptor on the surface of the T
1Lin Q, Rothbard JB, Garlington S, McGrane P,Wender P, Khavari PA:
Addition of a poly arginine linker to cyclosporin A facilitates transcuta-
neous delivery and topical inhibition of cutaneous in£ammation. J Invest
Dermatol 114:777, 2000 (abstr.)
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cell (Fig 1). At present, the speci¢c antigen(s) involved in AA is
not known, although a melanocyte-related protein has been
suggested in some patients (Gilhar et al, 2001). After T cell
recognition of the antigen, a second costimulatory signal must
be delivered by the APC to lead to full T cell activation.
Costimulation involves several interactions (some of which are
shown in Fig 1); these molecules are the targets of many
biologic drugs now used to block T cell activation.
Four biologic agents are brie£y described below. They include
etanercept, in£iximab, efalizumab, and alefacept. These agents
have been developed for rheumatoid arthritis, psoriatic arthritis,
Crohn’s disease, and psoriasis. None has been tested in AA, but,
because medications that are successful in treating psoriasis have
been e¡ective in treating AA, clinical trials in AA are warranted.
The nomenclature of the biologic therapies is regulated so that the
su⁄x of the name denotes the therapy’s class: -ximab denotes a
chimeric monoclonal antibody, as in in£iximab; -zumab denotes a
humanized monoclonal antibody, as in efalizumab; and cept denotes
a receptor^antibody fusion protein, as in etanercept and alefacept.
Etanercept (Enbrel) Etanercept is a human fusion protein that
inhibits the in£ammatory cytokine TNF-a. It is FDA approved
for the treatment of rheumatoid arthritis (since November 1998),
juvenile rheumatoid arthritis (since May 1999), and psoriatic
arthritis (since January 2002) and is given twice weekly as a
subcutaneous injection. Clinical trials with etanercept in
psoriasis have been promising (Mease et al, 2000; Gottlieb and
Weinstein, 2003). At present, the agent is considered to have a
good margin of safety in psoriasis, although safety related to its
long-term use needs to be determined.
In£iximab (Remicade) In£iximab inhibits the in£ammatory
cytokine TNF-a and is a chimeric (mouse/human) antibody. It is
FDA approved for the treatment of rheumatoid arthritis and
Crohn’s disease. Controlled clinical trials in psoriasis show
promise of in£iximab’s rapid e⁄cacy (Chaudhari et al, 2001). It is
administered by intravenous infusion over 90 minutes.
The long-term safety of TNF-a inhibition is being monitored
in North America and Europe. Rare instances of tuberculosis
activation, multiple sclerosis, positive antinuclear antibodies,
lymphoma, and pancytopenia have been reported (Gottlieb,
2003). Most patients with such side e¡ects were on concomitant
immunosuppressive therapy for rheumatoid arthritis or Crohn’s
disease, and no causal relationship has been established between
these events and the use of TNF-a inhibitors.
Efalizumab (Raptiva) Efalizumab is a humanized mono-
clonal antibody that has several e¡ects of potential therapeutic
bene¢t in AA. It binds CD11a, a component of LFA-1 that binds
to ICAM-1 on APCs, and thus it interrupts this costimulatory
signal (Fig 1). It also blocks T cell adhesion to endothelial cells
and T cell migration (tra⁄cking) into in£ammed tissues. In
phase II clinical trials, 62% of patients showed 50% improve-
ment as measured by the Psoriasis Activity and Severity Index
(PASI), and 30% showed 75% improvement. Other than mild
£u-like symptoms that subsided with continued use of the
medication, there were no signi¢cant infections in these clinical
studies (Papp et al, 2001; Gottlieb et al, in press). The drug is given
by subcutaneous injection once weekly by the patient. Appli-
cation for approval in the United States has been submitted.
Alefacept (Amevive) Alefacept is a fusion protein that induces
apoptosis in T cells expressing high levels of CD2. It also may
block the LFA-3/CD2 costimulatory signal (Fig 1). Alefacept
reduces high CD2-expressing memoryT cells in the circulation.
It is FDA approved (since February 2003) for the treatment of
psoriasis. Monitoring of the CD4þT cell count is required with
alefacept. In phase II trials in psoriasis, this agent has shown
e⁄cacy with an excellent safety pro¢le. In one psoriasis trial
(Krueger et al, 2002), 71% of patients showed 50% or greater
improvement in PASI, 40% had 75% or greater improvement,
and there was no increased incidence of infection. Some patients
had a remission for eight months, which may re£ect slow
repopulation of the skin with native T cells (Singri et al, 2002).
The medication is given once weekly either intramuscularly or
by an intravenous bolus (‘‘push’’).
Biologics in Development In addition to the agents descri-
bed, many other biologics are in development. For example,
CTLA4Ig is a fusion protein that blocks CD80/86 (B7)
costimulation with CD28 (Fig 1) and is administered by
intravenous infusion. Clinical trials have been conducted in
psoriasis (Abrams et al, 1999) and are in progress in rheumatoid
arthritis. As a word of caution, long-term incidence of auto-
Figure1. Antigen-presenting cell (APC)^
T cell interactions needed for T cell
activation. The MHC complex presents a
speci¢c antigen to the T cell receptor, re-
ferred to as signal 1. Multiple interactions
are needed for costimulation, referred to as
signal 2. Sites of blockade of Tcell activation
by three biologic agents are shown. ICAM-1
indicates intracellular adhesion molecule-1;
LFA, lymphocyte function-associated anti-
gen; MHC, major histocompatibility com-
plex; and TCR,T cell receptor.
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immune disease, infection, and cancer has yet to be deter-
mined for the biologic therapies.
IN THE FUTURE
The following concepts may not reach therapeutic fruition for
AA as soon as those described above. Conceptually, however,
they target speci¢c physiologic responses found in human or an-
imal AA and are based on the four strategies proposed by Gordon
and colleagues for rationally designed biologic therapies in psor-
iasis (Singri et al, 2002). Treatments that are e¡ective in psoriasis
have been used in AA, and some approaches are showing promise
in psoriasis clinical studies (Kirby and Gri⁄ths, 2002). They are
mentioned for this reason.
Reduction of pathogenic T cells Both CD4þand CD8þ
T cells are required and closely interact to maintain an AA
lesion on the human scalp (Gilhar et al, 2002). Not surprisingly,
depletion of either or both promotes hair regrowth in the AA
rat model (McElwee et al, 1996; McElwee et al, 1999). In psoriasis,
alefacept binds speci¢cally to T cells expressing high levels of
CD2 and, when given in therapeutic doses, reduces circulating
memory T cells. Other agents to reduce the number of
pathogenic T cells are in development.
Inhibition of T cell activation/migration Blockade of T cell
activation with CTLA4Ig has delayed AA onset in the mouse
model by blocking the costimulatory interaction of CD28-B7
(Carroll et al, 2002). CTLA4Ig is in clinical trials for rheumatoid
arthritis, and trials in AAwould be appropriate.
Blockade of T cell migration using an anti-CD44V10
monoclonal antibody prevents the onset of AA in the C3H/HeJ
mouse graft-induced model (Freyschmidt et al, 2001). CD44v10 is
a lymphocyte cell surface receptor found onTcells in lesional AA
skin; hence, the use of anti-CD44v10 antibodies might be a future
therapeutic approach to inhibit the development of AA.
Shifting a type 1 cytokine response to a type 2 cytokine
response The manipulation of the type 1/type 2 cytokine
balance by exogenously administered cytokines is a therapeutic
strategy termed immune deviation. Untreated AA is characterized
by a type 1 cytokine response, and successful treatment with a
contact sensitizer such as diphencyprone is associated with
increased expression of interleukin-10 (IL-10), a type 2 cytokine.
Another aspect of AA is that there is no destruction of hair
follicles in AA, and this has been attributed in part to a shift from
a type 1 cytokine response to a more chronic type 2 cytokine
immune pro¢le. For these reasons, administration of IL-10 is a
possible therapeutic approach for AA. In fact, recombinant human
IL-10 was given subcutaneously in a recent phase II trial in 10
patients with psoriasis, with antipsoriatic e¡ect con¢rmed by
histological examination (Asadullah et al, 1999). Initial positive
results have, however, been tempered by more negative results in
a double-blind, placebo-controlled study (Kimball et al, 2002).
Recently, IL-4 therapy, which also induces a type 2 cytokine
di¡erentiation, was given to patients with severe psoriasis and
produced signi¢cant clinical improvement (Ghoreschi et al, 2003).
This approach may thus have potential as a treatment for type
1^associated autoimmune diseases such as psoriasis and AA.
Blocking activity of in£ammatory cytokines Another
strategy is the selective targeting of speci¢c in£ammatory cyto-
kines. Two TNF-a inhibitors were described above. Expression
of the in£ammatory cytokine IFN-g is increased in psoriatic
lesions. A humanized monoclonal antibody against human
IFN-g (HuZAF) is in clinical trials in psoriasis and other type 1
cytokine^mediated diseases. If successful, this approach would be
desirable because global immune suppression is not produced by
blocking this cytokine (Krueger, 2002).
SUMMARY
AA has been established as aT cell-mediated autoimmune disease
with a type 1 cytokine pattern. New immunomodulators and
biologic therapies target speci¢c immunologic responses and of-
fer new strategies for treating pathogenicTcells and the cytokines
they produce. In the future, AA should receive ¢rst-line consid-
eration for clinical studies with new speci¢c therapies for T cell^
mediated in£ammatory diseases.
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